日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod

接受芬戈莫德治疗的多发性硬化症患者对第三剂 COVID-19 疫苗的免疫反应与淋巴细胞计数相关

Anat Achiron, Mathilda Mandel, Michael Gurevich, Sapir Dreyer-Alster, David Magalashvili, Polina Sonis, Mark Dolev, Shay Menascu, Gil Harari, Shlomo Flechter, Rina Falb

SARS-CoV-2 memory B and T cell profiles in mild COVID-19 convalescent patients

轻症 COVID-19 康复患者的 SARS-CoV-2 记忆 B 细胞和 T 细胞谱

Gurevich, Michael; Zilkha-Falb, Rina; Sonis, Polina; Magalashvili, David; Menascu, Shay; Flechter, Shlomo; Dolev, Mark; Mandel, Mathilda; Achiron, Anat

COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose

新冠疫苗在多发性硬化症患者中的接种:第三剂加强针的安全性和体液免疫效力

Dreyer-Alster, Sapir; Menascu, Shay; Mandel, Mathilda; Shirbint, Emanuel; Magalashvili, David; Dolev, Mark; Flechter, Shlomo; Givon, Uri; Guber, Diana; Stern, Yael; Miron, Shmuel; Polliack, Michael; Falb, Rina; Sonis, Polina; Gurevich, Michael; Achiron, Anat

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

接受高效疾病修饰疗法治疗的多发性硬化症患者对 COVID-19 mRNA 疫苗的体液免疫反应

Achiron, Anat; Mandel, Mathilda; Dreyer-Alster, Sapir; Harari, Gil; Magalashvili, David; Sonis, Polina; Dolev, Mark; Menascu, Shay; Flechter, Shlomo; Falb, Rina; Gurevich, Michael

Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

作者回复:关于接受高效疾病修饰疗法治疗的多发性硬化症患者对 COVID-19 mRNA 疫苗的体液免疫反应的通讯

Achiron, Anat; Mandel, Mathilda; Dreyer-Alster, Sapir; Harari, Gil; Magalashvili, David; Sonis, Polina; Dolev, Mark; Menascu, Shay; Flechter, Shlomo; Falb, Rina; Gurevich, Michael

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

辉瑞BNT162b2新冠疫苗接种后多发性硬化症患者的体液免疫反应:长达6个月的横断面研究

Achiron, Anat; Mandel, Mathilda; Dreyer-Alster, Sapir; Harari, Gil; Dolev, Mark; Menascu, Shay; Magalashvili, David; Flechter, Shlomo; Givon, Uri; Guber, Diana; Sonis, Polina; Zilkha-Falb, Rina; Gurevich, Michael

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

初始疾病修饰疗法与后期转化为继发性进展型多发性硬化症的关联

Brown, J William L; Coles, Alasdair; Horakova, Dana; Havrdova, Eva; Izquierdo, Guillermo; Prat, Alexandre; Girard, Marc; Duquette, Pierre; Trojano, Maria; Lugaresi, Alessandra; Bergamaschi, Roberto; Grammond, Pierre; Alroughani, Raed; Hupperts, Raymond; McCombe, Pamela; Van Pesch, Vincent; Sola, Patrizia; Ferraro, Diana; Grand'Maison, Francois; Terzi, Murat; Lechner-Scott, Jeannette; Flechter, Schlomo; Slee, Mark; Shaygannejad, Vahid; Pucci, Eugenio; Granella, Franco; Jokubaitis, Vilija; Willis, Mark; Rice, Claire; Scolding, Neil; Wilkins, Alastair; Pearson, Owen R; Ziemssen, Tjalf; Hutchinson, Michael; Harding, Katharine; Jones, Joanne; McGuigan, Christopher; Butzkueven, Helmut; Kalincik, Tomas; Robertson, Neil

Immunoglobulin free light chains in saliva: a potential marker for disease activity in multiple sclerosis

唾液中免疫球蛋白游离轻链:多发性硬化症疾病活动性的潜在标志物

Kaplan, B; Golderman, S; Ganelin-Cohen, E; Miniovitch, A; Korf, E; Ben-Zvi, I; Livneh, A; Flechter, S

Influence of histocompatibility genes on disease susceptibility and treatment response in patients with relapsing-remitting multiple sclerosis treated with interferon β-1a

组织相容性基因对接受干扰素β-1a治疗的复发缓解型多发性硬化症患者的疾病易感性和治疗反应的影响

Flechter, Shlomo; Klein, Tirza; Pollak, Lea